Mesoblast gets $4.3m R&D Tax Incentive rebate
22 July, 2013 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has received a $4.3m Tax Incentive reimbursement for its FY12 Australian R&D and plans to plough the funds back into its MPC development programs.
TGA survey: regulation of commercial IVDs
18 July, 2013The Therapeutic Goods Administration (TGA) invites manufacturers and sponsors of commercially produced in vitro diagnostic medical devices (IVDs) supplied in (or exported from) Australia to take part in a survey about the progress of the transition to the new regulatory framework for IVDs, introduced in 2010 and taking full effect on 1 July 2014.
Alchemia chairman steps down after 10 years
17 July, 2013 by Dylan Bushell-EmblingAlchemia’s (ASX:ACL) long-serving chairman, Mel Bridges, has left the company, while Timothy Hughes has joined as a non-executive director.
Starpharma names new business development VP
17 July, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has appointed a second vice president for business development, as the company prepares to ramp-up commercial discussions for lead product VivaGel.
PolyNovo’s NovoSorb evaluated for hernia repair
17 July, 2013 by Dylan Bushell-EmblingA US specialist device company is evaluating using PolyNovo’s NovoSorb technology for devices used in hernia repair surgery.
Bioniche expands reach for cow fertility product
17 July, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has secured regulatory approval for Folltropin - its FSH product for stimulating superovulation in cows - in seven more European markets.
Accelerator program for medical technology start-ups
16 July, 2013 by Susan WIlliamsonATP Innovations is looking for innovative medtech ideas for Ignition Labs’ seed accelerator program.
‘Guide for Life Science Company Directors’ open for comment
16 July, 2013AusBiotech, supported by the Victorian Government, has been working with an advisory committee to develop the Guide for Life Science Company Directors as a supporting document to the newly revised Code of Best Practice for Reporting by Life Sciences Companies (Ed 2). A draft is now available for comment until 15 August.
Phosphagenics gets ethics nod for acne trial
15 July, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has secured ethics approval for a phase II trial of an acne treatment candidate as part of its plans to diversify into the dermatology segment.
Promising early results from pSivida uveitis trial
12 July, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) said none of the eyes treated using its micro-insert experienced a recurrence in posterior uveitis during the first 12 months of its phase I/II trial.
Protagonist raises $14m for peptide discovery
11 July, 2013 by Dylan Bushell-EmblingUniversity of Queensland-based Protagonist Therapeutics has closed a $14m financing round to support its disulfide rich peptide (DRP) discovery program.
Patrys, Minomic and Starpharma secure ARC grants
11 July, 2013 by Dylan Bushell-EmblingThe ARC has awarded fresh Linkage Grants for collaborations between Macquarie University, Patrys (ASX:PAB) and Minomic, and between Monash University and Starpharma (ASX:SPL).
Biotech boards and doing business in China feature in July AusBiotech journal
11 July, 2013AusBiotech is pleased to provide you with the latest edition of the Australasian Biotechnology e-journal (Volume 23, Number 2).
PolyNovo eyes plastic surgery market for NovoSorb
10 July, 2013 by Dylan Bushell-EmblingCalzada (ASX:CZD) unit PolyNovo is teaming up with a group of US specialists to develop and commercialise products for the plastic surgery market based on polymer technology Novosorb.
